Glenmark Life Sciences Ltd. (ALIVUS) Share Price Hits Fresh 52-Week High

Glenmark Life Sciences Ltd. Share Price surged to Rs 1,209.9, marking a 4.37% rise and a fresh 52-week high of Rs 1,223.6. The market cap stands at Rs 14,231.67 crore.

Glenmark Life Sciences Ltd. Share Price has reached a fresh 52-week high, closing at Rs 1,209.9, up 4.37% from the previous close of Rs 1,159.2. The stock opened at Rs 1,174.4 and peaked at Rs 1,223.6 during the day. With a market capitalisation of Rs 14,231.67 crore, Glenmark Life Sciences Ltd. is attracting significant investor attention. This milestone highlights the stock's strong performance in the market, although the data does not specify a company-specific catalyst for this rise.

Glenmark Life Sciences Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,209.9
Previous Close	Rs 1,159.2
Today's Change	+Rs 50.7 (+4.37%)
Day Open	Rs 1,174.4
Fresh 52-Week High	Rs 1,223.6
Day Low	Rs 1,174.4
Current Volume	14,837
Turnover	Rs 1.8 crore
Market Capitalisation	Rs 14,231.67 crore

Glenmark Life Sciences Ltd. (ALIVUS) traded at Rs 1,209.9. versus the previous close of Rs 1,159.2, a rise of 4.37%. The stock opened at Rs 1,174.4, reached Rs 1,223.6, touched Rs 1,174.4. Reported volume was 14,837.

Today, Glenmark Life Sciences Ltd. Share Price opened at Rs 1,174.4, reaching a high of Rs 1,223.6 and a low of Rs 1,174.4. The stock closed at Rs 1,209.9, marking a 4.37% increase from the previous close. The turnover for the day was Rs 1.8 crore, with a volume of 14,837 shares traded. This price action reflects a robust upward movement, setting a new 52-week high and indicating strong market interest.

Glenmark Life Sciences Ltd. (ALIVUS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 14,231.67 crore
P/E Ratio	30.09x
P/B Ratio	0.44x
ROE	-2.89%
ROCE	-0.26%

Glenmark Life Sciences Ltd. was valued at a P/E ratio of 30.09x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	30.09x
Benchmark Median P/E	20.73x
Benchmark Average P/E	67.98x
Benchmark P/E Range	0x to 3,417.8x
Company P/B Ratio	0.44x
Benchmark Median P/B	1.91x
Company ROE	-2.89%
Benchmark Median ROE	10.7%
Company ROCE	-0.26%
Benchmark Median ROCE	13.13%
Company Market Capitalisation	Rs 14,231.67 crore
Benchmark Median Market Cap	Rs 130.49 crore

Glenmark Life Sciences Ltd. (ALIVUS) is classified under sector: Healthcare.

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 30.09x, which is above the benchmark median of 20.73x, a difference of +45.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Glenmark Life Sciences Ltd. (ALIVUS) has a ROE of -2.89%, which is below the benchmark median of 10.7%, a difference of -127.01%. Glenmark Life Sciences Ltd. (ALIVUS) has a ROCE of -0.26%, which is below the benchmark median of 13.13%, a difference of -101.98%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,931.84	30.09	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,683.28	39.84	8.11	28.21	26.35
Beta Drugs Ltd.	BETA	2,474.26	59.65	7.97	18.65	22.17
Sai Parenteral's Ltd.	SAIPARENT	2,416.82	169.49	3.13	13.9	12.97
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,414	34.44	6.97	-2.6	16.92

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 30.09x compared with the displayed peer median of 39.84x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Glenmark Life Sciences Ltd. (ALIVUS) has a market capitalisation of Rs 14,231.67 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Glenmark Life Sciences Ltd.

• Fresh 52-week high at Rs 1,223.6, indicating strong price momentum.
• Valuation metrics suggest a relatively inexpensive stock compared to sector averages.
• Significant market capitalisation within the Healthcare sector.
• Competitive positioning against peers with similar or higher P/E ratios.

About Glenmark Life Sciences Ltd.

Glenmark Life Sciences Ltd. operates in the Healthcare sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs). The company plays a crucial role in the pharmaceutical supply chain, providing essential components for drug formulation. With a strong emphasis on quality and innovation, Glenmark Life Sciences Ltd. serves a diverse range of clients globally, contributing to its substantial market presence.

Track Glenmark Life Sciences Ltd. Share Price on Univest

Use Glenmark Life Sciences Ltd. (ALIVUS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track Glenmark Life Sciences Ltd. Share Price, technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest for comprehensive analysis and informed decision-making.

Frequently Asked Questions

What is the current share price of Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. Share Price is currently Rs 1,209.9, marking a 4.37% increase from the previous close. The stock reached a fresh 52-week high of Rs 1,223.6 today. The stock moved 4.37% during the session.

What is Glenmark Life Sciences Ltd.'s market capitalisation?

Ans. Glenmark Life Sciences Ltd. has a market capitalisation of Rs 14,231.67 crore, positioning it as a significant player in the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.09x.

What are the valuation metrics for Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. has a P/E ratio of 30.09 and a P/B ratio of 0.44, indicating a relatively inexpensive valuation compared to sector averages. The company trades at a P/E ratio of 30.09x.

How does Glenmark Life Sciences Ltd. compare to its peers?

Ans. Glenmark Life Sciences Ltd. has a similar P/E ratio to Dishman Carbogen Amcis Ltd. but a larger market cap than its peers, highlighting its market prominence. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.

What is the sector context for Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. operates in the Healthcare sector, with a P/E median of 20.73 and a P/B median of 1.91, indicating a competitive landscape. The stock belongs to the Healthcare sector.

Where can I track Glenmark Life Sciences Ltd. Share Price?

Ans. Investors can track Glenmark Life Sciences Ltd. Share Price, technical indicators, and market insights on Univest for comprehensive analysis. The stock moved 4.37% during the session. The intraday range extended from Rs 1,174.4 to Rs 1,223.6.